A phase 1 study of XL019 a selective JAK2 inhibitor, in patients with primary myelofibrosis and, post-polycythemia vera/essential thrombocythemia myelofibrosis

被引：12
|
作者：
Verstovsek, Srdan [1 ]
Pardanani, Animesh D. [2 ]
Shah, Neil P. [3 ]
Sokol, Lubomir [4 ]
Wadleigh, Martha [5 ]
Gilliland, D. Gary
List, Alan F. [4 ]
Tefferi, Ayalew [2 ]
Kantarjian, Hagop M. [1 ]
Bui, Lynne A. [6 ]
Clary, Douglas O. [6 ]
机构：
[1] MD Anderson Canc Ctr, San Francisco, CA USA
[2] Mayo Clin, San Francisco, CA USA
[3] Univ Calif San Francisco, San Francisco, CA USA
[4] H Lee Moffitt Canc Ctr & Res Inst, San Francisco, CA USA
[5] Dana Farber Canc Inst, San Francisco, CA USA
[6] Exelixis Inc, San Francisco, CA USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.553.553
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
553
引用
收藏
页码：170A / 170A
页数：1
相关论文
共 50 条
  • [41] A phase I/II study of INCB018424, an oral, selective JAK inhibitor, in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF)
    Verstovsek, S.
    Kantarjian, H. M.
    Pardanani, A.
    Thomas, D. A.
    Cortes, J. E.
    Mesa, R.
    Hogan, W.
    Redman, J.
    Levy, R.
    Vaddi, K.
    Tefferi, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [42] Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
    Tam, Constantine S.
    Kantarjian, Hagop
    Cortes, Jorge
    Lynn, Alice
    Pierce, Sherry
    Zhou, Lingsha
    Keating, Michael J.
    Thomas, Deborah A.
    Verstovsek, Srdan
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) : 5587 - 5593
  • [43] Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project
    Mora, Barbara
    Giorgino, Toni
    Guglielmelli, Paola
    Rumi, Elisa
    Maffioli, Margherita
    Rambaldi, Alessandro
    Caramella, Marianna
    Komrokji, Rami
    Gotlib, Jason
    Kiladjian, Jean Jacques
    Cervantes, Francisco
    Devos, Timothy
    Palandri, Francesca
    De Stefano, Valerio
    Ruggeri, Marco
    Silver, Richard T.
    Benevolo, Giulia
    Albano, Francesco
    Cavalloni, Chiara
    Barraco, Daniela
    Merli, Michele
    Pietra, Daniela
    Casalone, Rosario
    Barbui, Tiziano
    Rotunno, Giada
    Cazzola, Mario
    Vannucchi, Alessandro Maria
    Passamonti, Francesco
    HAEMATOLOGICA, 2018, 103 (09) : E392 - E394
  • [44] A RUXOLITINIB INDIVIDUAL SUPPLY PROGRAM FOR PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF), OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)
    Barosi, G.
    Linardi, C.
    Ben Yehuda, D.
    Henrique Daumas Gabriel, A.
    Perez, J.
    Modi, A.
    Khan, M.
    Zweegman, S.
    Raymakers, R.
    Vianelli, N.
    Pakstyte, S.
    Willenbacher, W.
    Gisslinger, H.
    HAEMATOLOGICA, 2012, 97 : 321 - 321
  • [45] Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor
    Verstovsek, Srdan
    Tam, Constantine S.
    Wadleigh, Martha
    Sokol, Lubomir
    Smith, Catherine C.
    Bui, Lynne A.
    Song, Chunyan
    Clary, Douglas O.
    Olszynski, Patrycja
    Cortes, Jorge
    Kantarjian, Hagop
    Shah, Neil P.
    LEUKEMIA RESEARCH, 2014, 38 (03) : 316 - 322
  • [46] A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia
    Verstovsek, Srdan
    Mesa, Ruben A.
    Salama, Mohamed E.
    Li, Li
    Pitou, Celine
    Nunes, Fabio P.
    Price, Gregory L.
    Giles, Jennifer L.
    D'Souza, Deborah N.
    Walgren, Richard A.
    Prchal, Josef T.
    LEUKEMIA RESEARCH, 2017, 61 : 89 - 95
  • [47] A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia
    Verstovsek, Srdan
    Courby, Stephane
    Griesshammer, Martin
    Mesa, Ruben A.
    Brachmann, Carrie Baker
    Kawashima, Jun
    Maltzman, Julia D.
    Shao, Lixin
    Xin, Yan
    Huang, Daniel
    Bajel, Ashish
    LEUKEMIA RESEARCH, 2017, 60 : 11 - 17
  • [48] Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis
    Murata, Makoto
    Suzuki, Ritsuro
    Nishida, Tetsuya
    Shirane, Shuichi
    Shimazu, Yutaka
    Minami, Yosuke
    Mori, Takehiko
    Doki, Noriko
    Kanda, Yoshinobu
    Uchida, Naoyuki
    Tanaka, Masatsugu
    Ishikawa, Jun
    Togitani, Kazuto
    Fukuda, Takahiro
    Ichinohe, Tatsuo
    Atsuta, Yoshiko
    Nagamura-Inoue, Tokiko
    Kiyoi, Hitoshi
    INTERNAL MEDICINE, 2020, 59 (16) : 1947 - 1956
  • [49] Real-world clinical characteristics of post-essential thrombocythemia and post-polycythemia vera myelofibrosis
    Kotaro Shide
    Katsuto Takenaka
    Akira Kitanaka
    Akihiko Numata
    Takuro Kameda
    Takuji Yamauchi
    Atsushi Inagaki
    Shohei Mizuno
    Akiyoshi Takami
    Shinichi Ito
    Masao Hagihara
    Kensuke Usuki
    Takaaki Maekawa
    Kazutaka Sunami
    Yasunori Ueda
    Miyuki Tsutsui
    Miki Ando
    Norio Komatsu
    Keiya Ozawa
    Mineo Kurokawa
    Shunya Arai
    Kinuko Mitani
    Koichi Akashi
    Kazuya Shimoda
    Annals of Hematology, 2024, 103 : 97 - 103
  • [50] Real-world clinical characteristics of post-essential thrombocythemia and post-polycythemia vera myelofibrosis
    Shide, Kotaro
    Takenaka, Katsuto
    Kitanaka, Akira
    Numata, Akihiko
    Kameda, Takuro
    Yamauchi, Takuji
    Inagaki, Atsushi
    Mizuno, Shohei
    Takami, Akiyoshi
    Ito, Shinichi
    Hagihara, Masao
    Usuki, Kensuke
    Maekawa, Takaaki
    Sunami, Kazutaka
    Ueda, Yasunori
    Tsutsui, Miyuki
    Ando, Miki
    Komatsu, Norio
    Ozawa, Keiya
    Kurokawa, Mineo
    Arai, Shunya
    Mitani, Kinuko
    Akashi, Koichi
    Shimoda, Kazuya
    ANNALS OF HEMATOLOGY, 2024, 103 (01) : 97 - 103
12345